Table 1 Clinico-pathological characteristics, treatment received, and ERα-36 expression in the patient cohort tested (160 patients)
From: ERα-36 regulates progesterone receptor activity in breast cancer
Characteristic | Number | Percent | |
|---|---|---|---|
Age group (years) | < 50 | 51 | 31.9 |
> 50 | 109 | 68.1 | |
Menopausal status | Pre | 57 | 35.6 |
Post | 103 | 74.4 | |
Tumor size (cm) | < 2 | 68 | 42.5 |
> 2 | 92 | 57.5 | |
Axillary LN metastasis | No | 76 | 47.5 |
Yes | 84 | 52.5 | |
SBR grade | I | 26 | 16.3 |
II | 71 | 44.4 | |
III | 63 | 39.4 | |
ERα-66 status | Negative | 14 | 8.8 |
Positive | 145 | 90.6 | |
Missing | 1 | ||
PR status | Negative | 40 | 25.3 |
Positive | 118 | 74.7 | |
Missing | 2 | ||
HER2 status | Negative | 129 | 84.9 |
Overexpressed | 23 | 15.1 | |
Missing | 8 | ||
Breast cancer subtype | Luminal | 142 | 91.6 |
Basal | 10 | 6.5 | |
HER2 driven | 3 | 1.9 | |
Missing | 5 | ||
Adjuvant Hormonal treatment | No | 27 | 16.9 |
Yes | 133 | 83.1 | |
Adjuvant (or neoadj) chemotherapy | No | 59 | 36.9 |
Yes | 101 | 63.1 | |
ERα-36 | Low | 95 | 59.4 |
High | 65 | 40.6 | |